WallStreetZenWallStreetZen

NASDAQ: CRDL
Cardiol Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRDL

Based on 3 analysts offering 12 month price targets for Cardiol Therapeutics Inc.
Min Forecast
$8.00+275.59%
Avg Forecast
$9.00+322.54%
Max Forecast
$10.00+369.48%

Should I buy or sell CRDL stock?

Based on 3 analysts offering ratings for Cardiol Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRDL stock forecasts and price targets.

CRDL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-26
lockedlocked$00.00+00.00%2024-06-14
lockedlocked$00.00+00.00%2024-05-23

1 of 1

Forecast return on equity

Is CRDL forecast to generate an efficient return?
Company
19.7%
Industry
38.88%
Market
80.66%
CRDL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRDL forecast to generate an efficient return on assets?
Company
12.7%
Industry
17.45%
CRDL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRDL earnings per share forecast

What is CRDL's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.34
Avg 2 year Forecast
-$0.33
Avg 3 year Forecast
-$0.33

CRDL revenue forecast

What is CRDL's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$41.9M
Avg 2 year Forecast
$125.4M
Avg 3 year Forecast
$231.8M

CRDL vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
CRDL$2.13$9.00+322.54%Strong Buy
OPTN$1.27$4.00+214.96%Strong Buy
ASRT$1.54$3.25+111.04%Strong Buy
ZOM$0.15N/AN/A
LFCR$5.01N/AN/A

Cardiol Therapeutics Stock Forecast FAQ

Is Cardiol Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CRDL) stock is to Strong Buy CRDL stock.

Out of 3 analysts, 2 (66.67%) are recommending CRDL as a Strong Buy, 1 (33.33%) are recommending CRDL as a Buy, 0 (0%) are recommending CRDL as a Hold, 0 (0%) are recommending CRDL as a Sell, and 0 (0%) are recommending CRDL as a Strong Sell.

If you're new to stock investing, here's how to buy Cardiol Therapeutics stock.

What is CRDL's earnings growth forecast for 2024-2026?

(NASDAQ: CRDL) Cardiol Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 20.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 21.68%.

Cardiol Therapeutics's earnings in 2024 is -$22,057,363.On average, 3 Wall Street analysts forecast CRDL's earnings for 2024 to be -$22,004,684, with the lowest CRDL earnings forecast at -$23,716,088, and the highest CRDL earnings forecast at -$19,870,236. On average, 3 Wall Street analysts forecast CRDL's earnings for 2025 to be -$21,152,187, with the lowest CRDL earnings forecast at -$23,075,113, and the highest CRDL earnings forecast at -$17,947,310.

In 2026, CRDL is forecast to generate -$21,363,709 in earnings, with the lowest earnings forecast at -$24,998,039 and the highest earnings forecast at -$17,306,335.

What is CRDL's revenue growth forecast for 2027-2029?

(NASDAQ: CRDL) Cardiol Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.61%.

Cardiol Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast CRDL's revenue for 2027 to be $2,684,404,808, with the lowest CRDL revenue forecast at $2,652,997,015, and the highest CRDL revenue forecast at $2,715,812,600. On average, 2 Wall Street analysts forecast CRDL's revenue for 2028 to be $8,036,869,551, with the lowest CRDL revenue forecast at $7,594,276,065, and the highest CRDL revenue forecast at $8,479,463,037.

In 2029, CRDL is forecast to generate $14,860,372,746 in revenue, with the lowest revenue forecast at $14,860,372,746 and the highest revenue forecast at $14,860,372,746.

What is CRDL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CRDL) forecast ROA is 12.7%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 17.45%.

What is CRDL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CRDL price target, the average CRDL price target is $9.00, with the highest CRDL stock price forecast at $10.00 and the lowest CRDL stock price forecast at $8.00.

On average, Wall Street analysts predict that Cardiol Therapeutics's share price could reach $9.00 by Jun 26, 2025. The average Cardiol Therapeutics stock price prediction forecasts a potential upside of 322.54% from the current CRDL share price of $2.13.

What is CRDL's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CRDL) Cardiol Therapeutics's current Earnings Per Share (EPS) is -$0.34. On average, analysts forecast that CRDL's EPS will be -$0.34 for 2024, with the lowest EPS forecast at -$0.37, and the highest EPS forecast at -$0.31. On average, analysts forecast that CRDL's EPS will be -$0.33 for 2025, with the lowest EPS forecast at -$0.36, and the highest EPS forecast at -$0.28. In 2026, CRDL's EPS is forecast to hit -$0.33 (min: -$0.39, max: -$0.27).

What is CRDL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CRDL) forecast ROE is 19.7%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.